A NEW HAIRY CELL LEUKEMIA CELL LINE

Award Information
Agency:
Department of Health and Human Services
Amount:
$49,875.00
Program:
SBIR
Contract:
N/A
Solitcitation Year:
N/A
Solicitation Number:
N/A
Branch:
N/A
Award Year:
1992
Phase:
Phase I
Agency Tracking Number:
19090
Solicitation Topic Code:
N/A
Small Business Information
Cp Li Biomedical Research
2000 North 14th Street, Suite 740, Arlington, VA, 22201
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 Shi-hua Wu
 (703) 558-3400
Business Contact
Phone: () -
Research Institution
N/A
Abstract
A NEW CELL LINE, DESIGNATED "HDS", WAS ESTABLISHED IN A SUSPENSION CULTURE DERIVED FROM THE PERIPHERAL BLOOD OF A PATIENT WITH HAIRY CELL LEUKEMIA (HCL), AND THE PERSON HAS DEVELOPED CLINICAL RESISTANCE TO ALPHA-INTERFERON THERAPY. THE PATIENT EXHIBITED A CLINICAL PICTURE CHARACTERISTIC OF HCL, INCLUDING SPLENOMEGALY, CYTOPENIAS, AND TARTRATE-RESISTANT ACID PHOSPHATASE (TRAP)-POSITIVE "HAIRY" CELLS IN BLOOD AND MARROW. ULTRA-STRUCTURAL ANALYSIS OF THE CULTURED CELLS, AT THE SINGLE CELL LEVEL, REVEALED A DISPLAY OF MICROVILLI, MIXED WITH RUFFLES ON THE CELL SURFACE IN A CLASSICAL HAIRY CELL PATTERN. THE ESTABLISHED CELL LINE HAS THE PHENOTYPE OF A B-TYPE CELL AS JUDGED BY CYTOCHEMISTRY AND IMMUNOLABELING. HDS CELLS HAVE HLA-DR AND CD19 SURFACE ANTIGENS, BUT SHOWN NEGATIVE RESULTS FOR EARLY B(CD10) AND EARLY T (CD2, CD3) CELL MARKERS. THESE CELLS ARE NEGATIVE FOR HCL MARKERS SUCH AS CD11C, CD22, AND CD25. HDS CELLS ARE ALSO NEGATIVE FOR T-CELLS, MYELOCYTIC, AND MONOCYTIC MARKERS. IN PHASE I AND II, STUDIES ARE PLANNED TO DETERMINE THE EXACT DIFFERENTIATION STAGE OF THE HDS CELLS, AND TO DEVELOP A NOVEL SUBCLASS OF B-TYPE HCL CELLS, HDS CELLS FOR CLINICAL ASSAYS, DIAGNOSIS, DETECTION AND TREATMENT. THIS WORK IS IMPORTANT IN CLINICAL HEMATOLOGY RESEARCH DIAGNOSIS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government